Medicine and Dentistry
Epidermal Growth Factor Receptor
77%
Non Small Cell Lung Cancer
66%
Mutant
55%
Brain Metastasis
44%
Exon
33%
Chemotherapy
22%
Tyrosine-Kinase Inhibitor
22%
Epidermal Growth Factor Receptor Kinase Inhibitor
22%
Patient
22%
Lung Cancer
11%
Long Term Survival
11%
Development
11%
Immunotherapy
11%
Brain Radiation
11%
Resistance Mutation
11%
Erlotinib
11%
Mortality
11%
Gefitinib
11%
Osimertinib
11%
Therapeutic Procedure
11%
Inpatient
11%
Physics
Epidermal Growth Factor
100%
Lung
77%
Mutant
55%
Inhibitor
44%
Mutation
44%
Receptor Tyrosine Kinase
22%
Survival
11%
Radiation
11%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
77%
Non Small Cell Lung Cancer
66%
Brain Metastasis
44%
Protein Tyrosine Kinase Inhibitor
22%
Epidermal Growth Factor Receptor Kinase Inhibitor
22%
Lung Cancer
11%
Immunotherapy
11%
Long Term Survival
11%
Erlotinib
11%
Gefitinib
11%
Mortality
11%
Death
11%
Afatinib
11%
Osimertinib
11%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
77%
Mutant
55%
Mutation
44%
Exon
33%
Receptor Tyrosine Kinase Inhibitors
22%
Wild Type
11%
Development
11%
Erlotinib
11%
Long Term Survival
11%
Afatinib
11%
Radiation
11%
Gefitinib
11%
Mortality
11%
Neuroscience
Brain
55%
Metastasis
44%
Exon
33%
Receptor Tyrosine Kinase Inhibitors
22%
Immunotherapy
11%
Chemotherapy
11%
Erlotinib
11%
Gefitinib
11%
Osimertinib
11%
Afatinib
11%